Inhibition of BET or CDK7 has been used to target MYC-driven tumours in different contexts, as MYC expression in tumours is frequently maintained at a high level by an associated super-enhancer region (Sengupta and George, 2017). This evidence concerns the gene MYC and neoplasm.